These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8052965)

  • 61. Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery.
    Maroney SA; Peterson JA; Zwifelhofer W; Martinez ND; Yan K; Bercovitz RS; Woods RK; Mast AE
    Thromb Haemost; 2018 Sep; 118(9):1545-1555. PubMed ID: 30086574
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dermatan sulphate as an antithrombotic drug.
    Nenci GG
    Pathophysiol Haemost Thromb; 2002; 32(5-6):303-7. PubMed ID: 13679662
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure.
    Boccardo P; Melacini D; Rota S; Mecca G; Boletta A; Casiraghi F; Gianese F
    Nephrol Dial Transplant; 1997 Nov; 12(11):2349-54. PubMed ID: 9394322
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Heparin: Effects upon the Glycocalyx and Endothelial Cells.
    Spiess BD
    J Extra Corpor Technol; 2017 Sep; 49(3):192-197. PubMed ID: 28979043
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A low molecular weight heparin alters the fetal coagulation system in the pregnant sheep.
    Andrew M; Ofosu F; Fernandez F; Jefferies A; Hirsh J; Mitchell L; Buchanan MR
    Thromb Haemost; 1986 Jun; 55(3):342-6. PubMed ID: 3750264
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Aggressive early surgical strategy in patients with intracranial hemorrhage: a new cardiopulmonary bypass option.
    Yamazato T; Oyama N; Fujii T; Abe N; Ikemiya Y; YutakaTamashiro ; Munakata H
    Gen Thorac Cardiovasc Surg; 2022 Jul; 70(7):602-610. PubMed ID: 34813003
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intravenous Dabigatran Provides Adequate Anticoagulation for Cardiopulmonary Bypass Using a Rabbit Model.
    Nadtochiy SM; Stefanos T; Angona RE; Darrow N; Jones CCPK; Feng C; Algahim M; LeMoine D; Westcott R; Anderson B; Swartz MF; Eaton MP
    Anesthesiology; 2023 May; 138(5):523-532. PubMed ID: 36821759
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The correction of disorders in the blood coagulating system during the surgical treatment of patients with pulmonary tuberculosis].
    Priĭmak AA; Makinskiĭ AI; Ivan'ko TP; Makarova VV
    Vrach Delo; 1991 Sep; (9):54-7. PubMed ID: 1759433
    [No Abstract]   [Full Text] [Related]  

  • 69. Neutralization of dermatan sulfate in vitro and in vivo by protamine sulfate and polybrene.
    Sié P; Cremers B; Dupouy D; Caranobe C; Dol F; Boneu B
    Thromb Res; 1989 Apr; 54(1):63-74. PubMed ID: 2727957
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Blood anesthesia for cardiopulmonary bypass.
    Gorman JH; Edmunds LH
    J Card Surg; 1995 May; 10(3):270-9. PubMed ID: 7626879
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dermatan sulphate in acute leukaemia.
    Cofrancesco E; Boschetti C; Leonardi P; Cortellaro M
    Lancet; 1992 May; 339(8802):1177-8. PubMed ID: 1349404
    [No Abstract]   [Full Text] [Related]  

  • 72. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation.
    Van Ryn-McKenna J; Ofosu FA; Hirsh J; Buchanan MR
    Br J Haematol; 1989 Feb; 71(2):265-9. PubMed ID: 2522314
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacodynamic and efficacy profile of TGN 255, a novel direct thrombin inhibitor, in canine cardiopulmonary bypass and simulated mitral valve repair.
    Nelson DA; Nelson KT; Miller MW; Dupe R; Chahwala SB; Kennedy A; Chander C; Fossum TW
    J Extra Corpor Technol; 2008 Jun; 40(2):116-22. PubMed ID: 18705547
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of different glycosaminoglycans in a guinea-pig carotid artery thrombosis model.
    Mattar L; Maffei FH; Nader HB; Dietrich CP; Curi PR
    Thromb Res; 1994 Sep; 75(6):591-9. PubMed ID: 7831678
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect.
    Fernandez F; N'guyen P; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
    Thromb Res; 1986 Aug; 43(4):491-5. PubMed ID: 3764805
    [No Abstract]   [Full Text] [Related]  

  • 76. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers.
    Dawes J; McLaren M; Forbes C; Belch JJ; Lane DA; Bray B; McEwen J; Houin G; Gianese F
    Br J Clin Pharmacol; 1991 Sep; 32(3):361-6. PubMed ID: 1777373
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Isolation and characterization of dermatan sulphate from pig skin.
    Konador A
    Mater Med Pol; 1974; 6(2):89-94. PubMed ID: 4431248
    [No Abstract]   [Full Text] [Related]  

  • 78. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate.
    Barbanti M; Calanni F; Babbini M; Bergonzini G; Parma B; Marchi E; Wassermann A
    Thromb Res; 1993 Sep; 71(5):417-22. PubMed ID: 8236168
    [No Abstract]   [Full Text] [Related]  

  • 79. [Circulating heparin-like anticoagulant--2 cases of successful therapy].
    Jarosová A; Filip V; Monhart V; Limberk B
    Vnitr Lek; 1992 May; 38(5):513-7. PubMed ID: 1509723
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Structural basis for the anticoagulant activity of heparin. 2. Relationship of anticoagulant activity to the thermodynamics and fluorescence fading kinetics of acridine orange-heparin complexes.
    Menter JM; Hurst RE; Corliss DA; West SS; Abrahamson EW
    Biochemistry; 1979 Oct; 18(20):4288-92. PubMed ID: 486425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.